20 hours ago
(NewsNation) — ALS, or amyotrophic lateral sclerosis, is a fatal neurological disease with no cure. For people who carry genetic mutations linked to the disease, one of the biggest challenges is not knowing when symptoms might begin.
New research funded by the National Institutes of Health could help change that.
Researchers have developed a blood test that may predict when an at-risk person is likely to develop ALS symptoms, providing a potential window for preventive treatment before irreversible nerve damage occurs.
The study identified protein markers in the blood that can help predict the onset of symptoms, a transition known as phenoconversion.
Dr. Anthony Youn says popular peptides 'aren't studied enough' in humans
#Help #blood #national #researchers
New research funded by the National Institutes of Health could help change that.
Researchers have developed a blood test that may predict when an at-risk person is likely to develop ALS symptoms, providing a potential window for preventive treatment before irreversible nerve damage occurs.
The study identified protein markers in the blood that can help predict the onset of symptoms, a transition known as phenoconversion.
Dr. Anthony Youn says popular peptides 'aren't studied enough' in humans
#Help #blood #national #researchers
2 days ago
Our ****** ysts just identified a stock with the potential to be the next Nvidia. Tell us how you invest and we'll show you why it's our #1 pick. Tap here.
Management attributes the significant Q2 outperformance to a rally in finished product markets, specifically fat and protein prices, alongside favorable trade-related developments.
The Feed Ingredients segment benefited from robust biofuel demand and tightening global fish meal supplies, which strengthened protein values and supported improved gross margins.
Operational excellence programs, including contract management and price risk optimization, are delivering on the Investor Day promise to generate $150 million to $300 million in additional EBITDA over three years.
The Food segment is undergoing a structural shift from gelatin to higher-margin collagen, with collagen currently generating 2.5x to 3x the margin of traditional gelatin products.
#protein #segment #million
Management attributes the significant Q2 outperformance to a rally in finished product markets, specifically fat and protein prices, alongside favorable trade-related developments.
The Feed Ingredients segment benefited from robust biofuel demand and tightening global fish meal supplies, which strengthened protein values and supported improved gross margins.
Operational excellence programs, including contract management and price risk optimization, are delivering on the Investor Day promise to generate $150 million to $300 million in additional EBITDA over three years.
The Food segment is undergoing a structural shift from gelatin to higher-margin collagen, with collagen currently generating 2.5x to 3x the margin of traditional gelatin products.
#protein #segment #million
2 days ago
Few foods were as well-positioned as jerky to take advantage of the recent wave of interest in protein-rich foods. And few companies in that industry have seen a spike in sales like Jack Link's jerky.
But despite the company's current market leadership position (brick-and-mortar retail sales reportedly topped $1.6 billion in 2025), it once was struggling to find direction after filing for bankruptcy.
Jeff Bezos backs a platform that lets anyone invest in rental homes for as little as $100 — 6 ways to build wealth like a landlord without actually being one
Dave Ramsey warns nearly 50% of Americans are making 1 big Social Security mistake — here's what it is and 3 simple steps to fix it ASAP
The tax breaks in Trump's 'big beautiful bill' expire after 2028 — and experts say most people won't act in time. What to do before the window closes
#jerky #like
But despite the company's current market leadership position (brick-and-mortar retail sales reportedly topped $1.6 billion in 2025), it once was struggling to find direction after filing for bankruptcy.
Jeff Bezos backs a platform that lets anyone invest in rental homes for as little as $100 — 6 ways to build wealth like a landlord without actually being one
Dave Ramsey warns nearly 50% of Americans are making 1 big Social Security mistake — here's what it is and 3 simple steps to fix it ASAP
The tax breaks in Trump's 'big beautiful bill' expire after 2028 — and experts say most people won't act in time. What to do before the window closes
#jerky #like
2 days ago
A major scientific review is challenging the idea that more protein is always better.
The review, led by pathologist and biomedical researcher Dudley Lamming and published in the journal Cell Press Blue, examined more than 350 studies involving humans, mice, insects, yeast, and other organisms.
The review found that eating less protein, or less of certain amino acids that make up protein, may turn on body processes linked to healthier aging, as well as metabolism, the process by which the body turns food and drinks into energy.
Filadendron/STOCK PHOTO/Getty Images - PHOTO: Stock photo of a person eating a chicken salad.
Protein is now added to lattes, cereal, chips, ramen, and many other foods that were never traditionally marketed as protein-rich. The message seems clear: More protein must be better.
#body
The review, led by pathologist and biomedical researcher Dudley Lamming and published in the journal Cell Press Blue, examined more than 350 studies involving humans, mice, insects, yeast, and other organisms.
The review found that eating less protein, or less of certain amino acids that make up protein, may turn on body processes linked to healthier aging, as well as metabolism, the process by which the body turns food and drinks into energy.
Filadendron/STOCK PHOTO/Getty Images - PHOTO: Stock photo of a person eating a chicken salad.
Protein is now added to lattes, cereal, chips, ramen, and many other foods that were never traditionally marketed as protein-rich. The message seems clear: More protein must be better.
#body
2 days ago
Felicia, the flagship brand of Andriani Societa Benefit, announces a multi-year partnership with Juventus Football Club, becoming the Club's Official Healthy Food Partner. The agreement brings together two organisations that share values, including innovation, the pursuit of excellence and a strong focus on quality of life.
Felicia and Juventus aim to promote increasingly conscious consumption habits, highlighting the role of a balanced diet as an integral part of an active lifestyle.
Felicia will be present throughout the Juventus ecosystem through a structured program that includes brand visibility, digital content and dedicated experiences for supporters and the Bianconeri community. The agreement includes a presence at Allianz Stadium during Serie A and Italian Cup matches, activities at the Juventus Training Center and the production of exclusive content developed in collaboration with Juventus Creator Lab, providing direct access to Juventus' extensive global social media audience of more than 190 million followers.
The project will also directly involve the Club's sporting operations. Felicia products will become part of the Men's First Team's nutritional plan, confirming the shared focus on quality, innovation and wellbeing. The decision is consistent with the brand's commitment to promoting a healthy lifestyle inspired by the Mediterranean diet and biodiversity at the table, through products that are naturally gluten-free, rich in plant-based protein and whole grains and also suitable for athletes.
"This partnership marks an important milestone in Felicia's journey to strengthen its presence in the world of sport through the promotion of a positive and responsible approach to nutrition," said Marco Lentini, Marketing Director of Andriani Societa Benefit. "Working with an organisation such as Juventus means helping to raise awareness of issues related to wellbeing, taste, and the value of food biodiversity. It is the meeting of shared values and a common ability to create authentic connections between people, generations and communities.
#societa
Felicia and Juventus aim to promote increasingly conscious consumption habits, highlighting the role of a balanced diet as an integral part of an active lifestyle.
Felicia will be present throughout the Juventus ecosystem through a structured program that includes brand visibility, digital content and dedicated experiences for supporters and the Bianconeri community. The agreement includes a presence at Allianz Stadium during Serie A and Italian Cup matches, activities at the Juventus Training Center and the production of exclusive content developed in collaboration with Juventus Creator Lab, providing direct access to Juventus' extensive global social media audience of more than 190 million followers.
The project will also directly involve the Club's sporting operations. Felicia products will become part of the Men's First Team's nutritional plan, confirming the shared focus on quality, innovation and wellbeing. The decision is consistent with the brand's commitment to promoting a healthy lifestyle inspired by the Mediterranean diet and biodiversity at the table, through products that are naturally gluten-free, rich in plant-based protein and whole grains and also suitable for athletes.
"This partnership marks an important milestone in Felicia's journey to strengthen its presence in the world of sport through the promotion of a positive and responsible approach to nutrition," said Marco Lentini, Marketing Director of Andriani Societa Benefit. "Working with an organisation such as Juventus means helping to raise awareness of issues related to wellbeing, taste, and the value of food biodiversity. It is the meeting of shared values and a common ability to create authentic connections between people, generations and communities.
#societa
3 days ago
When menopause comes knocking, it brings a metabolic nosedive and weakened muscles along with it. Those two go hand in hand (we'll explain in a minute) but the upshot is a host of joint and muscle injuries you might not realize are hormonal. Back in 2019, Shania Twain was in the same boat.
At the time, Twain was doing a residency in Las Vegas and experiencing what she now realizes was a "raging period of menopause," the singer revealed to People. In the new cover story, Shania shares that she was dehydrated and undernourished from not eating enough protein and lacking key nutrients.
More from Flow ***** e
Michelle Monaghan's Secret to Staying Game for Anything at 50
"I wasn't eating enough salt, I wasn't retaining any water, and I wasn't drinking enough water," Twain recalled, citing the dry Nevada climate. "It was just this perfect storm for disaster."
#wasn 't #shania
At the time, Twain was doing a residency in Las Vegas and experiencing what she now realizes was a "raging period of menopause," the singer revealed to People. In the new cover story, Shania shares that she was dehydrated and undernourished from not eating enough protein and lacking key nutrients.
More from Flow ***** e
Michelle Monaghan's Secret to Staying Game for Anything at 50
"I wasn't eating enough salt, I wasn't retaining any water, and I wasn't drinking enough water," Twain recalled, citing the dry Nevada climate. "It was just this perfect storm for disaster."
#wasn 't #shania
10 days ago
Hot dogs, peanuts, popcorn, and pretzels have long been staples of the ballpark experience. Yet in Seattle, baseball fans have embraced a snack that surprises many first-time visitors: toasted grasshoppers. What began as a specialty dish at a local restaurant quickly evolved into one of the most talked-about concessions at Seattle Mariners games. The unusual offering not only challenged expectations about stadium food but also introduced thousands of people to a traditional ingredient that has been enjoyed in parts of the world for centuries.
The story begins at Poquitos, a Mexican-inspired restaurant in Seattle led by executive chef Manny Arce. When the restaurant first opened, Arce added toasted grasshoppers, known in Mexican cuisine as chapulines, to the menu as a novelty. Chapulines have been eaten for generations, particularly in the Mexican state of Oaxaca, where they are considered a popular street food and a rich source of protein. Seasoned simply with salt, lime, and chili, they offer a crunchy texture and a savory flavor that many diners compare to roasted sunflower seeds with a hint of spice.
Although the snack attracted curious customers at the restaurant, its popularity reached an entirely new level when the Seattle Mariners expressed interest in featuring it at what is now known as T-Mobile Park, formerly Safeco Field. After sampling the product, the organization decided it would make a unique addition to the stadium's food lineup. The response exceeded every expectation. Fans eager to try something different lined up to buy the toasted grasshoppers, and supplies disappeared almost immediately during games.
What initially seemed like a niche offering quickly became a stadium sensation. Chef Arce expected that his first shipment of approximately 50 pounds would last several weeks. Instead, it sold out in a single day. As demand continued to grow, the numbers became astonishing. More than 300,000 individual servings were eventually sold, requiring well over 1,000 pounds of grasshoppers to keep up with fan interest. On many game days, vendors ran out before the first inning had even ended.
The success of the snack reflects changing attitudes toward food and the growing willingness of consumers to explore unfamiliar culinary traditions. Around the world, edible insects are recognized as nutritious, environmentally sustainable sources of protein that require fewer natural resources than conventional livestock. While many people still view the idea with hesitation, others appreciate the opportunity to experience flavors that are common in different cultures.
#many #first #mexican
The story begins at Poquitos, a Mexican-inspired restaurant in Seattle led by executive chef Manny Arce. When the restaurant first opened, Arce added toasted grasshoppers, known in Mexican cuisine as chapulines, to the menu as a novelty. Chapulines have been eaten for generations, particularly in the Mexican state of Oaxaca, where they are considered a popular street food and a rich source of protein. Seasoned simply with salt, lime, and chili, they offer a crunchy texture and a savory flavor that many diners compare to roasted sunflower seeds with a hint of spice.
Although the snack attracted curious customers at the restaurant, its popularity reached an entirely new level when the Seattle Mariners expressed interest in featuring it at what is now known as T-Mobile Park, formerly Safeco Field. After sampling the product, the organization decided it would make a unique addition to the stadium's food lineup. The response exceeded every expectation. Fans eager to try something different lined up to buy the toasted grasshoppers, and supplies disappeared almost immediately during games.
What initially seemed like a niche offering quickly became a stadium sensation. Chef Arce expected that his first shipment of approximately 50 pounds would last several weeks. Instead, it sold out in a single day. As demand continued to grow, the numbers became astonishing. More than 300,000 individual servings were eventually sold, requiring well over 1,000 pounds of grasshoppers to keep up with fan interest. On many game days, vendors ran out before the first inning had even ended.
The success of the snack reflects changing attitudes toward food and the growing willingness of consumers to explore unfamiliar culinary traditions. Around the world, edible insects are recognized as nutritious, environmentally sustainable sources of protein that require fewer natural resources than conventional livestock. While many people still view the idea with hesitation, others appreciate the opportunity to experience flavors that are common in different cultures.
#many #first #mexican
11 days ago
Coca-Cola (KO) disclosed a ransomware attack suspended Fairlife's U.S. production with no restoration timeline, threatening grocery shelf availability nationwide.
Past food and beverage ransomware attacks on Arizona Beverages and UNFI caused weeks of empty shelves, and Fairlife has few protein dairy substitutes.
Act now: the ***** yst who called NVIDIA in 2010 just named his top 10 AI stocks — and Coca-Cola didn't make the cut. Grab the names FREE today.
One of the fastest-growing brands in the American dairy aisle just went dark, and a cyberattack is the reason.
In a securities filing on July 16, 2026, Coca-Cola (NYSE:KO) disclosed that its Fairlife dairy subsidiary was hit by a ransomware attack that breached its IT systems, including production-related systems. Fairlife's U.S. production operations are "temporarily suspended," though Canadian operations are unaffected. The Fairlife hack is now rippling toward grocery shelves, and the Coca-Cola ransomware disclosure leaves the key question unanswered: when production comes back.
#suspended
Past food and beverage ransomware attacks on Arizona Beverages and UNFI caused weeks of empty shelves, and Fairlife has few protein dairy substitutes.
Act now: the ***** yst who called NVIDIA in 2010 just named his top 10 AI stocks — and Coca-Cola didn't make the cut. Grab the names FREE today.
One of the fastest-growing brands in the American dairy aisle just went dark, and a cyberattack is the reason.
In a securities filing on July 16, 2026, Coca-Cola (NYSE:KO) disclosed that its Fairlife dairy subsidiary was hit by a ransomware attack that breached its IT systems, including production-related systems. Fairlife's U.S. production operations are "temporarily suspended," though Canadian operations are unaffected. The Fairlife hack is now rippling toward grocery shelves, and the Coca-Cola ransomware disclosure leaves the key question unanswered: when production comes back.
#suspended
16 days ago
Madison Small Cap Fund, managed by Madison Funds, released its Q2 2026 investor letter. A copy of the letter can be downloaded here. The small-cap market showed exceptional strength in Q2, largely due to anticipated peace in the Middle East. The Russell 2000 Index began to rally, propelled by Information Technology, Health Care, and Industrials. The Madison Small Cap Fund (Class I) returned 12.7% in the quarter, underperforming the Russell 2000's 21.5% and Russell 2500's 20.2%. While strong gains were seen in Info Tech investments, recent investments in underperforming software companies negatively impacted overall performance. Nevertheless, confidence in the long-term potential of these software investments remains high. The firm is optimistic about small caps, noting their recent outperformance over large caps, recovery in certain software sectors, and improvements in some housing stocks toward the end of the second quarter. Please review the Fund's top five holdings to gain insights into their key selections for 2026.
In its Q2 2026 investor letter, Madison Small Cap Fund highlighted The Simply Good Foods Company (NASDAQ:SMPL). The Simply Good Foods Company (NASDAQ:SMPL) is a Denver based consumer-packaged food and beverage company. On July 16, 2026, The Simply Good Foods Company (NASDAQ:SMPL) closed at $12.07 per share, reflecting a market capitalization of $1.07 billion. The Simply Good Foods Company (NASDAQ:SMPL) posted a one-month return of -4.43%, while its shares lost 63.12% over the past 52 weeks.
Madison Small Cap Fund stated the following regarding The Simply Good Foods Company (NASDAQ:SMPL) in its Q2 2026 investor update:
"The Simply Good Foods Company (NASDAQ:SMPL) is a consumer staples company that owns the Atkins and Quest protein and snack food brands. Over the past few years, the company has faced multiple headwinds, including cost inflation, the rationalization of the Atkins brand, and the integration of the recently acquired OWYN brand. While the rationalization of Atkins led to severe top-line headwinds, we remained patient as the more important Quest brand maintained its growth. The recent slowdown in the core Quest protein bar business led to a loss of confidence in management and a leadership change. We decided to move on to better opportunities."
The Simply Good Foods Company (NASDAQ:SMPL) is not on our list of 40 Most Popular Stocks Among Hedge Funds Heading Into 2026. According to our database, 33 hedge fund portfolios held The Simply Good Foods Company (NASDAQ:SMPL) at the end of the first quarter, compared to 35 in the previous quarter. While we acknowledge the potential of The Simply Good Foods Company (NASDAQ:SMPL) as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI st
In its Q2 2026 investor letter, Madison Small Cap Fund highlighted The Simply Good Foods Company (NASDAQ:SMPL). The Simply Good Foods Company (NASDAQ:SMPL) is a Denver based consumer-packaged food and beverage company. On July 16, 2026, The Simply Good Foods Company (NASDAQ:SMPL) closed at $12.07 per share, reflecting a market capitalization of $1.07 billion. The Simply Good Foods Company (NASDAQ:SMPL) posted a one-month return of -4.43%, while its shares lost 63.12% over the past 52 weeks.
Madison Small Cap Fund stated the following regarding The Simply Good Foods Company (NASDAQ:SMPL) in its Q2 2026 investor update:
"The Simply Good Foods Company (NASDAQ:SMPL) is a consumer staples company that owns the Atkins and Quest protein and snack food brands. Over the past few years, the company has faced multiple headwinds, including cost inflation, the rationalization of the Atkins brand, and the integration of the recently acquired OWYN brand. While the rationalization of Atkins led to severe top-line headwinds, we remained patient as the more important Quest brand maintained its growth. The recent slowdown in the core Quest protein bar business led to a loss of confidence in management and a leadership change. We decided to move on to better opportunities."
The Simply Good Foods Company (NASDAQ:SMPL) is not on our list of 40 Most Popular Stocks Among Hedge Funds Heading Into 2026. According to our database, 33 hedge fund portfolios held The Simply Good Foods Company (NASDAQ:SMPL) at the end of the first quarter, compared to 35 in the previous quarter. While we acknowledge the potential of The Simply Good Foods Company (NASDAQ:SMPL) as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI st
22 days ago
A rival drug failure can sometimes move a biotech stock almost as much as a company's own clinical data.
That is what happened to BridgeBio on July 9.
BridgeBio (BBIO) shares jumped after AstraZeneca and Ionis said Wainua failed to meet the main goal in a late-stage trial for transthyretin-mediated amyloid cardiomyopathy, or ATTR-CM, a heart disease caused by protein buildup that can make it harder for the heart to pump blood.
BridgeBio stock was recently trading at $89.86, up 14.7% from the previous close. The stock opened at $84 and traded as high as $93.31 during July 9's session.
The rally added roughly $2.2 billion to BridgeBio's market value based on its intraday market capitalization. The move shows investors were not just reacting to a failed trial. They were reassessing the competitive field around a drug BridgeBio already sells.
That is what happened to BridgeBio on July 9.
BridgeBio (BBIO) shares jumped after AstraZeneca and Ionis said Wainua failed to meet the main goal in a late-stage trial for transthyretin-mediated amyloid cardiomyopathy, or ATTR-CM, a heart disease caused by protein buildup that can make it harder for the heart to pump blood.
BridgeBio stock was recently trading at $89.86, up 14.7% from the previous close. The stock opened at $84 and traded as high as $93.31 during July 9's session.
The rally added roughly $2.2 billion to BridgeBio's market value based on its intraday market capitalization. The move shows investors were not just reacting to a failed trial. They were reassessing the competitive field around a drug BridgeBio already sells.
23 days ago
Erling Haaland has helped lead the Norwegian national team to the quarterfinals of the 2026 World Cup and in the process has become a global soccer sensation on and off the pitch.
Ahead of the highly-anticipated Norway vs. England match in Miami on Saturday, get to know more below about the Gen Z striker who has transcended the tournament with his unique personality.
Whether it's leading his team in a celebratory viking row chant after a win, surging to the top of Spotify charts or an sharing a glimpse into his high-protein diet with his 60 million Instagram followers -- which is more than 10 times the population of the country he represents -- the 25-year-old has amassed serious star power throughout this World Cup.
Erling, who was born in Leeds, England, before moving to Norway where he was raised and started his soccer career, made his international debut with Norway in September 2019.
"I lived in England for three and a half or four years," Haaland said in an interview last season, according to ESPN. "I lived in Norway for such a long time so it was natural for me to choose Norway.
Ahead of the highly-anticipated Norway vs. England match in Miami on Saturday, get to know more below about the Gen Z striker who has transcended the tournament with his unique personality.
Whether it's leading his team in a celebratory viking row chant after a win, surging to the top of Spotify charts or an sharing a glimpse into his high-protein diet with his 60 million Instagram followers -- which is more than 10 times the population of the country he represents -- the 25-year-old has amassed serious star power throughout this World Cup.
Erling, who was born in Leeds, England, before moving to Norway where he was raised and started his soccer career, made his international debut with Norway in September 2019.
"I lived in England for three and a half or four years," Haaland said in an interview last season, according to ESPN. "I lived in Norway for such a long time so it was natural for me to choose Norway.
23 days ago
Biohaven Ltd. (NYSE:BHVN) is one of the 10 Best Performing American Stocks in June 2026.
On June 30, 2026, Biohaven Ltd. (NYSE:BHVN) announced the completion of enrollment in RISE3, a pivotal Phase 2/3 randomized, double-blind, placebo-controlled study evaluating opakalim for refractory focal epilepsy. Opakalim is Biohaven's selective Kv7.2/7.3 channel activator, and top-line results from the study are expected in 2H 2026.
On June 29, Biohaven announced enrollment of the first patient in the pivotal Phase 3 trial of BHV-1300 for Graves' disease. BHV-1300 is the first MoDE extracellular protein degrader, described by the company as a novel small molecule IgG1, 2, and 4 degrader that uses the body's clearance machinery to eliminate the IgG1 TSHR autoantibody driving Graves' disease.
On June 26, Deutsche Bank raised the firm's price target on Biohaven to $20 from $15 and kept a Buy rating on the shares. Deutsche Bank said the company's troriluzole in spinocerebellar ataxia could be the next beneficiary of recent FDA reversals.
Miriam Doerr Martin Frommherz/Shutterstock.com
On June 30, 2026, Biohaven Ltd. (NYSE:BHVN) announced the completion of enrollment in RISE3, a pivotal Phase 2/3 randomized, double-blind, placebo-controlled study evaluating opakalim for refractory focal epilepsy. Opakalim is Biohaven's selective Kv7.2/7.3 channel activator, and top-line results from the study are expected in 2H 2026.
On June 29, Biohaven announced enrollment of the first patient in the pivotal Phase 3 trial of BHV-1300 for Graves' disease. BHV-1300 is the first MoDE extracellular protein degrader, described by the company as a novel small molecule IgG1, 2, and 4 degrader that uses the body's clearance machinery to eliminate the IgG1 TSHR autoantibody driving Graves' disease.
On June 26, Deutsche Bank raised the firm's price target on Biohaven to $20 from $15 and kept a Buy rating on the shares. Deutsche Bank said the company's troriluzole in spinocerebellar ataxia could be the next beneficiary of recent FDA reversals.
Miriam Doerr Martin Frommherz/Shutterstock.com
23 days ago
We recently compiled a list of the 10 Best Innovative Healthcare Stocks to Buy Now. Crinetics Pharmaceuticals, Inc. (NASDAQ:CRNX) is one of the best healthcare stocks on our list.
TheFly reported on July 2 that UBS ******* yst Ashwani Verma initiated coverage of CRNX with a Buy rating and a $55 price target. The ******* yst noted that the stock's 44% decline since mid-January presents an appealing opportunity for investors. UBS highlighted CRNX's pipeline as having multiple potential catalysts, supported by programs with strong chances of clinical success. The firm expressed the highest confidence in the Phase 3 atumelnant program for congenital adrenal hyperplasia and projects peak sales potential of approximately $2.0 billion.
In other news, on July 6, Vertex Pharmaceuticals and Crinetics Pharmaceuticals, Inc. (NASDAQ:CRNX) announced a definitive agreement under which Vertex will acquire Crinetics for $85.00 per share in cash, representing an equity value of approximately $10 billion, or about $8.8 billion after accounting for estimated acquired cash. The transaction received unanimous approval from both companies' boards and is expected to close in the third quarter of 2026. Vertex stated that CRNX's endocrine-focused portfolio, including PALSONIFY and atumelnant, aligns with its strategy of developing transformative medicines for diseases with significant unmet needs. The acquisition is expected to support Vertex's revenue growth, with the combined ******* ets projected to provide more than $5 billion in potential peak annual revenue.
Crinteics Pharmaceuticals, Inc. (NASDAQ:CRNX) is a clinical-stage biopharmaceutical company focused on developing oral, non-peptide therapies for endocrine diseases and tumors by targeting G-protein-coupled receptors (GPCRs). Its key programs include PALSONIFY (paltusotine), an FDA- and EMA-approved oral treatment for acromegaly; atremelnant, a Phase 3 therapy for congenital adrenal hyperplasia and Cushing's syndrome; and a pipeline targeting conditions such as Graves' disease, obesity, and other endocrine disorders, and this is what makes the company innovative.
While we acknowledge the potential of CRNX as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock.
TheFly reported on July 2 that UBS ******* yst Ashwani Verma initiated coverage of CRNX with a Buy rating and a $55 price target. The ******* yst noted that the stock's 44% decline since mid-January presents an appealing opportunity for investors. UBS highlighted CRNX's pipeline as having multiple potential catalysts, supported by programs with strong chances of clinical success. The firm expressed the highest confidence in the Phase 3 atumelnant program for congenital adrenal hyperplasia and projects peak sales potential of approximately $2.0 billion.
In other news, on July 6, Vertex Pharmaceuticals and Crinetics Pharmaceuticals, Inc. (NASDAQ:CRNX) announced a definitive agreement under which Vertex will acquire Crinetics for $85.00 per share in cash, representing an equity value of approximately $10 billion, or about $8.8 billion after accounting for estimated acquired cash. The transaction received unanimous approval from both companies' boards and is expected to close in the third quarter of 2026. Vertex stated that CRNX's endocrine-focused portfolio, including PALSONIFY and atumelnant, aligns with its strategy of developing transformative medicines for diseases with significant unmet needs. The acquisition is expected to support Vertex's revenue growth, with the combined ******* ets projected to provide more than $5 billion in potential peak annual revenue.
Crinteics Pharmaceuticals, Inc. (NASDAQ:CRNX) is a clinical-stage biopharmaceutical company focused on developing oral, non-peptide therapies for endocrine diseases and tumors by targeting G-protein-coupled receptors (GPCRs). Its key programs include PALSONIFY (paltusotine), an FDA- and EMA-approved oral treatment for acromegaly; atremelnant, a Phase 3 therapy for congenital adrenal hyperplasia and Cushing's syndrome; and a pipeline targeting conditions such as Graves' disease, obesity, and other endocrine disorders, and this is what makes the company innovative.
While we acknowledge the potential of CRNX as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock.
25 days ago
(NewsNation) — Your gut bacteria may influence hormone-related cancer risk, researchers say.
The bacteria living in your gut may play a much larger role in hormone-related cancers than scientists previously believed, according to a new review published in the journal npj Biofilms and Microbiomes.
Researchers ***** yzed existing studies examining how the gut microbiome — the trillions of bacteria and other microbes that live in the digestive tract — interacts with the body's hormone system.
While scientists have long known gut bacteria help regulate estrogen, the review suggests the microbiome acts as an active partner in hormone signaling, influencing inflammation, metabolism and immune responses that may affect cancer development.
New protein controls how the body stores, burns fat: study
The bacteria living in your gut may play a much larger role in hormone-related cancers than scientists previously believed, according to a new review published in the journal npj Biofilms and Microbiomes.
Researchers ***** yzed existing studies examining how the gut microbiome — the trillions of bacteria and other microbes that live in the digestive tract — interacts with the body's hormone system.
While scientists have long known gut bacteria help regulate estrogen, the review suggests the microbiome acts as an active partner in hormone signaling, influencing inflammation, metabolism and immune responses that may affect cancer development.
New protein controls how the body stores, burns fat: study
30 days ago
Vitamin Well Group is merging with EMPWR, the manufacturer of the sports-nutrition firm's Barebells protein bars.
The financial terms of the deal, announced by Cinven, one of Vitamin Well's private-equity backers, were not disclosed.
Under the agreement, EMPWR's owner Waterland Private Equity, will retain a minority stake in the enlarged business.
In a statement, Cinven, which invested in Vitamin Well in 2024, described EMPWR as an "important manufacturing partner" for the business.
Cinven said the deal "unlocks the ability to increase investments in capacity and pursue significant volume growth opportunities".
The financial terms of the deal, announced by Cinven, one of Vitamin Well's private-equity backers, were not disclosed.
Under the agreement, EMPWR's owner Waterland Private Equity, will retain a minority stake in the enlarged business.
In a statement, Cinven, which invested in Vitamin Well in 2024, described EMPWR as an "important manufacturing partner" for the business.
Cinven said the deal "unlocks the ability to increase investments in capacity and pursue significant volume growth opportunities".
30 days ago
Vaxcyte Inc. (NASDAQ:PCVX) is one of the 8 Hidden Multibagger Stocks to Buy Now. On June 18, Mizuho Securities ******* yst Salim Syed reiterated a Buy rating on Vaxcyte Inc. (NASDAQ:PCVX) with a price target of $163. The firm's price target reflects a significant 180% upside from current levels.
Earlier on June 16, PCVX announced an update regarding its ongoing clinical study. The company is conducting an early-stage clinical trial of VAX-A1, a vaccine designed to protect against Group A strep infections. The study will evaluate the safety, tolerability, and immunogenicity of VAX-A1 in healthy young adults. The trial is testing three different dose levels of the vaccine against a placebo. It is administered via muscle injection and is designed to support the immune system.
If the trial shows positive results, the vaccine could allow the company to enter a new market for preventing Group A strep infections. This could boost investor confidence in the company and support the stock's valuation. However, disappointing results could increase concerns about the program and shift attention toward larger vaccine competitors such as Pfizer and GSK.
Vaxcyte Inc. (NASDAQ:PCVX) is a clinical-stage vaccine innovation company that develops conjugate and novel protein vaccines to prevent or treat bacterial infectious diseases. The company develops a variety of vaccines, and its major candidate is VAX-24. The company was formerly known as SutroVax, Inc. and changed its name to Vaxcyte, Inc. in May 2020. It was incorporated in 2013 and is headquartered in San Carlos, California.
While we acknowledge the potential of PCVX as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock.
Earlier on June 16, PCVX announced an update regarding its ongoing clinical study. The company is conducting an early-stage clinical trial of VAX-A1, a vaccine designed to protect against Group A strep infections. The study will evaluate the safety, tolerability, and immunogenicity of VAX-A1 in healthy young adults. The trial is testing three different dose levels of the vaccine against a placebo. It is administered via muscle injection and is designed to support the immune system.
If the trial shows positive results, the vaccine could allow the company to enter a new market for preventing Group A strep infections. This could boost investor confidence in the company and support the stock's valuation. However, disappointing results could increase concerns about the program and shift attention toward larger vaccine competitors such as Pfizer and GSK.
Vaxcyte Inc. (NASDAQ:PCVX) is a clinical-stage vaccine innovation company that develops conjugate and novel protein vaccines to prevent or treat bacterial infectious diseases. The company develops a variety of vaccines, and its major candidate is VAX-24. The company was formerly known as SutroVax, Inc. and changed its name to Vaxcyte, Inc. in May 2020. It was incorporated in 2013 and is headquartered in San Carlos, California.
While we acknowledge the potential of PCVX as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock.
1 month ago
Concerned about an AI bubble? Sign up for The Daily Upside for smart and actionable market news, built for investors.
One part of people's budgets is untouchable no matter how thin their wallets get, and that's Fido's portion. The only segment of General Mills' sales in North America that rose in the fourth quarter was its pet business, which includes brands like Blue Buffalo and Tiki Cat. The rest of its earnings, reported yesterday, weren't as rosy.
The company, which owns brands including Cheerios and Betty Crocker, posted a $2 billion loss last quarter, mainly because of non-cash items. Revenue rose 1% as shoppers skimped, opting for smaller package sizes and sale items.
General Mills said yesterday it'll try to scrape together $3 billion in cost savings over the next four years, all while innovating in its products. Investors seemed to like the sound of the cereal company's lean and protein-packed plan, pushing its stock up about 9% yesterday.
Sign up for The Daily Upside at no cost for premium **** ysis on all your favorite stocks.
One part of people's budgets is untouchable no matter how thin their wallets get, and that's Fido's portion. The only segment of General Mills' sales in North America that rose in the fourth quarter was its pet business, which includes brands like Blue Buffalo and Tiki Cat. The rest of its earnings, reported yesterday, weren't as rosy.
The company, which owns brands including Cheerios and Betty Crocker, posted a $2 billion loss last quarter, mainly because of non-cash items. Revenue rose 1% as shoppers skimped, opting for smaller package sizes and sale items.
General Mills said yesterday it'll try to scrape together $3 billion in cost savings over the next four years, all while innovating in its products. Investors seemed to like the sound of the cereal company's lean and protein-packed plan, pushing its stock up about 9% yesterday.
Sign up for The Daily Upside at no cost for premium **** ysis on all your favorite stocks.
1 month ago
NVIDIA Corporation (NASDAQ:NVDA) is one of the high growth stocks to buy right now. On June 23, NVIDIA introduced the BioNeMo Agent Toolkit, a new software suite providing domain-specific tools designed to enable AI agents to accelerate scientific discovery in life sciences. By integrating over a decade of NVIDIA's libraries and models, the toolkit allows AI systems to perform complex tasks such as protein design, molecular docking, and genomic ****** ysis, acting as a "scientific toolbox" for research-oriented AI.
The toolkit enables agents to gather evidence, reason through findings, and execute computational experiments, essentially providing them with the expertise of a research ****** istant combined with the speed of a supercomputer. Powered by NVIDIA's NIM microservices and other core technologies, the platform is already being adopted by over 50 organizations (including major pharmaceutical companies and research institutions) to streamline workflows in drug discovery and biotechnology.
By allowing AI agents to understand and execute scientific processes autonomously, NVIDIA Corporation (NASDAQ:NVDA) aims to shift the paradigm of research toward faster, iterative design cycles. Collaborations with leaders like the University of Washington's Institute for Protein Design have already demonstrated significant performance gains, highlighting the toolkit's potential to dramatically reduce the time and cost required to solve complex problems in biology, chemistry, and medicine.
NVIDIA Corporation (NASDAQ:NVDA) is a fabless semiconductor and AI computing company that designs GPUs, AI accelerators, Application Programming Interfaces (APIs), and system-on-a-chip units. Through its CUDA ecosystem, the company enables industries ranging from autonomous vehicles to scientific research by advancing AI, accelerated computing, and data center infrastructure.
While we acknowledge the potential of NVDA as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock.
The toolkit enables agents to gather evidence, reason through findings, and execute computational experiments, essentially providing them with the expertise of a research ****** istant combined with the speed of a supercomputer. Powered by NVIDIA's NIM microservices and other core technologies, the platform is already being adopted by over 50 organizations (including major pharmaceutical companies and research institutions) to streamline workflows in drug discovery and biotechnology.
By allowing AI agents to understand and execute scientific processes autonomously, NVIDIA Corporation (NASDAQ:NVDA) aims to shift the paradigm of research toward faster, iterative design cycles. Collaborations with leaders like the University of Washington's Institute for Protein Design have already demonstrated significant performance gains, highlighting the toolkit's potential to dramatically reduce the time and cost required to solve complex problems in biology, chemistry, and medicine.
NVIDIA Corporation (NASDAQ:NVDA) is a fabless semiconductor and AI computing company that designs GPUs, AI accelerators, Application Programming Interfaces (APIs), and system-on-a-chip units. Through its CUDA ecosystem, the company enables industries ranging from autonomous vehicles to scientific research by advancing AI, accelerated computing, and data center infrastructure.
While we acknowledge the potential of NVDA as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock.
1 month ago
Rotisserie chicken has become a popular dinner staple for many American households amid rising food costs and a consumer shift toward protein-rich meals.
A new Consumer Reports ****** ysis reviewed rotisserie chicken from 10 different grocery stores to help shoppers easily identify the best pick for any price and palate.
The latest ****** ysis from Consumer Reports looked at rotisserie chicken from four national retailers and six regional grocers and evaluated each option based on the criteria of taste, nutrition and potential exposure to chemicals from plastic packaging.
Sam's Club took the top spot in the Consumer Reports rankings for taste. Testers praised its moist texture, deep-roasted flavor and seasoning.
Sam's Club was also among the most affordable options, priced at an average $4.98 per chicken.
A new Consumer Reports ****** ysis reviewed rotisserie chicken from 10 different grocery stores to help shoppers easily identify the best pick for any price and palate.
The latest ****** ysis from Consumer Reports looked at rotisserie chicken from four national retailers and six regional grocers and evaluated each option based on the criteria of taste, nutrition and potential exposure to chemicals from plastic packaging.
Sam's Club took the top spot in the Consumer Reports rankings for taste. Testers praised its moist texture, deep-roasted flavor and seasoning.
Sam's Club was also among the most affordable options, priced at an average $4.98 per chicken.
1 month ago
Updated June 23, 2026 5:18 pm ET
Listen
(4 min)
The latest Market Talks covering the Health Care sector. Published exclusively on Dow Jones Newswires at 4:20 ET, 12:20 ET and 16:50 ET.
1346 ET – SandboxAQ, an AI and quantum technology company, is partnering with Nvidia on an AI-powered drug discovery tool. The tool uses a platform from Nvidia and a large quantitative AI model from SandboxAQ to predict how molecules will interact with G protein-coupled receptors, a group of proteins which the company says are targeted by about one-third of all approved drugs, including GLP-1 medicines. “The reason why it’s been so difficult in drug discovery is that it takes so long to synthesize each potential new candidate drug, test it in a laboratory,” SandboxAQ CEO Jack Hidary says in a CNBC interview. “Now we can move to virtual screening and testing, but with models that are really high fidelity with our bodies.” (elias.schisgallwsj.com)
Listen
(4 min)
The latest Market Talks covering the Health Care sector. Published exclusively on Dow Jones Newswires at 4:20 ET, 12:20 ET and 16:50 ET.
1346 ET – SandboxAQ, an AI and quantum technology company, is partnering with Nvidia on an AI-powered drug discovery tool. The tool uses a platform from Nvidia and a large quantitative AI model from SandboxAQ to predict how molecules will interact with G protein-coupled receptors, a group of proteins which the company says are targeted by about one-third of all approved drugs, including GLP-1 medicines. “The reason why it’s been so difficult in drug discovery is that it takes so long to synthesize each potential new candidate drug, test it in a laboratory,” SandboxAQ CEO Jack Hidary says in a CNBC interview. “Now we can move to virtual screening and testing, but with models that are really high fidelity with our bodies.” (elias.schisgallwsj.com)
1 month ago
Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) is one of the most promising healthcare stocks according to Wall Street **** ysts. On June 10, GENESIS Pharma announced the expansion of its commercial partnership with Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) to cover four Nordic countries, that is, Sweden, Finland, Denmark, and Norway. GENESIS is an Athens-based biopharma company and the expanded collaboration gives it rights to commercialize Alnylam's RNAi therapeutics for serious heart muscle diseases and rare genetic conditions across the new territory.
The two companies started to work together in 2019, and at that time, the collaboration only covered Southeast Europe. Without the four additional countries, the collaboration covers 13 markets.
RNAi, or RNA interference, is Alnylam's proprietary technology that silences the genes responsible for producing disease-causing proteins. In short, it works by cutting off diseases at a molecular level before they fully take hold. This technology is a key part of the company's portfolio.
The expanded relationship means that Alnylam now has four new markets for the technology. According to Norton Oliveira, Senior Vice-President and Head of Partner and Emerging Markets at Alnylam, the expansion also means that the company "can continue to address the needs of even more patients and their families."
For Constantinos Evripides, Managing Director of GENESIS, the expanded relationship is an important push the company needed to strengthen their European footprint. "By combining Alnylam's pioneering science with our strong regional expertise in bringing innovation closer to patients, we continue to expand our reach and enhance the value we deliver across healthcare systems," Evripides said.
The two companies started to work together in 2019, and at that time, the collaboration only covered Southeast Europe. Without the four additional countries, the collaboration covers 13 markets.
RNAi, or RNA interference, is Alnylam's proprietary technology that silences the genes responsible for producing disease-causing proteins. In short, it works by cutting off diseases at a molecular level before they fully take hold. This technology is a key part of the company's portfolio.
The expanded relationship means that Alnylam now has four new markets for the technology. According to Norton Oliveira, Senior Vice-President and Head of Partner and Emerging Markets at Alnylam, the expansion also means that the company "can continue to address the needs of even more patients and their families."
For Constantinos Evripides, Managing Director of GENESIS, the expanded relationship is an important push the company needed to strengthen their European footprint. "By combining Alnylam's pioneering science with our strong regional expertise in bringing innovation closer to patients, we continue to expand our reach and enhance the value we deliver across healthcare systems," Evripides said.
1 month ago
Is ABSI a good stock to buy? We came across a bullish thesis on Absci Corporation on TradersPro's Substack. In this article, we will summarize the bulls' thesis on ABSI. Absci Corporation's share was trading at $7.27 as of June 15th.
Pressmaster/Shutterstock.com
Absci Corporation (ABSI) is a clinical-stage biopharmaceutical company focused on transforming drug discovery through the use of generative artificial intelligence, positioning itself at the forefront of a rapidly growing trend toward AI-enabled drug development. The company's lead program, ABS-201, is an antibody-based therapy designed to treat androgenetic alopecia, or pattern hair loss, by targeting a protein pathway involved in hair follicle biology.
Read More: 15 AI Stocks That Are Quietly Making Investors Rich
Read More: Undervalued AI Stock Poised For Massive Gains: 10000% Upside Potential
Pressmaster/Shutterstock.com
Absci Corporation (ABSI) is a clinical-stage biopharmaceutical company focused on transforming drug discovery through the use of generative artificial intelligence, positioning itself at the forefront of a rapidly growing trend toward AI-enabled drug development. The company's lead program, ABS-201, is an antibody-based therapy designed to treat androgenetic alopecia, or pattern hair loss, by targeting a protein pathway involved in hair follicle biology.
Read More: 15 AI Stocks That Are Quietly Making Investors Rich
Read More: Undervalued AI Stock Poised For Massive Gains: 10000% Upside Potential
1 month ago
Renaissance Investment Management, an investment management company, released its Q1 2026 "Large Cap Growth Strategy." A copy of the letter can be downloaded here. Stocks fell sharply in the first quarter due to the Iran conflict. The Energy and Materials sectors outperformed, Financials and Consumer Discretionary lagged. Large-cap stocks underperformed smaller-cap stocks, and Value outperformed Growth. The portfolio outperformed the S&P 500's -4.3% return but lagged the Russell 1000 Growth Index, which fell 9.8%. In this uncertain environment, the firm remains aware of the risks and emerging investment opportunities. In addition, you can check the Strategy's top 5 holdings for its best picks for 2026.
In its first-quarter 2026 investor letter, Renaissance Investment Large Cap Growth Strategy highlighted Zoetis Inc. (NYSE:ZTS) as anewly added position. Zoetis Inc. (NYSE:ZTS) is an animal health company focused on animal health medications, vaccines, and diagnostic products. On June 16, 2026, Zoetis Inc. (NYSE:ZTS) closed at $79.33 per share. One-month return of Zoetis Inc. (NYSE:ZTS) was 0.04%, and its shares lost 48.57% over the past 52 weeks. Zoetis Inc. (NYSE:ZTS) has a market capitalization of $33.25 billion.
Renaissance Investment Large Cap Growth Strategy stated the following regarding Zoetis Inc. (NYSE:ZTS) in its Q1 2026 investor letter:
"In the first quarter, we made several changes to our portfolio as market rotation provided us with several opportunities to upgrade the quality of the portfolio. In March, we added a new position in the Health Care sector with Zoetis Inc. (NYSE:ZTS), the global leader in vaccines and pharmaceuticals for both the companion animal and livestock markets. Zoetis has faced difficult growth comparisons since the latter part of 2022, after an initial spike in demand caused by COVID-driven pet adoptions wore off and operational missteps in new drug launches hampered growth. However, we believe that revenue is positioned to reaccelerate as COVID-era pets approach the age when preventive and protective treatments begin, driving demand for professional veterinary services. We particularly like the company's new drug pipeline, with new drug launches over the next four years targeting cancer, kidney, heart, obesity, and anxiety treatments. In addition, we believe that increasing demand for protein consumption and a relaunch of the company's pain medication will likewise help reverse recent revenue deceleration."
Zoetis Inc. (NYSE:ZTS) is not on our list of 40 Most Popular Stocks Among Hedge Funds Heading Into 2026. According to our database, 57 hedge fund portfolios held Zoetis Inc. (NYSE:ZTS) at the end of the first quarter, compared to 69 in the previous quarter. While we acknowledge the potential of Zoetis Inc. (NYSE:ZTS) as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit
In its first-quarter 2026 investor letter, Renaissance Investment Large Cap Growth Strategy highlighted Zoetis Inc. (NYSE:ZTS) as anewly added position. Zoetis Inc. (NYSE:ZTS) is an animal health company focused on animal health medications, vaccines, and diagnostic products. On June 16, 2026, Zoetis Inc. (NYSE:ZTS) closed at $79.33 per share. One-month return of Zoetis Inc. (NYSE:ZTS) was 0.04%, and its shares lost 48.57% over the past 52 weeks. Zoetis Inc. (NYSE:ZTS) has a market capitalization of $33.25 billion.
Renaissance Investment Large Cap Growth Strategy stated the following regarding Zoetis Inc. (NYSE:ZTS) in its Q1 2026 investor letter:
"In the first quarter, we made several changes to our portfolio as market rotation provided us with several opportunities to upgrade the quality of the portfolio. In March, we added a new position in the Health Care sector with Zoetis Inc. (NYSE:ZTS), the global leader in vaccines and pharmaceuticals for both the companion animal and livestock markets. Zoetis has faced difficult growth comparisons since the latter part of 2022, after an initial spike in demand caused by COVID-driven pet adoptions wore off and operational missteps in new drug launches hampered growth. However, we believe that revenue is positioned to reaccelerate as COVID-era pets approach the age when preventive and protective treatments begin, driving demand for professional veterinary services. We particularly like the company's new drug pipeline, with new drug launches over the next four years targeting cancer, kidney, heart, obesity, and anxiety treatments. In addition, we believe that increasing demand for protein consumption and a relaunch of the company's pain medication will likewise help reverse recent revenue deceleration."
Zoetis Inc. (NYSE:ZTS) is not on our list of 40 Most Popular Stocks Among Hedge Funds Heading Into 2026. According to our database, 57 hedge fund portfolios held Zoetis Inc. (NYSE:ZTS) at the end of the first quarter, compared to 69 in the previous quarter. While we acknowledge the potential of Zoetis Inc. (NYSE:ZTS) as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit
2 months ago
Danone has reportedly taken Chobani to court again in the US, accusing its rival of misleading information on serving sizes.
According to multiple media reports, Danone alleges Chobani is incorrectly marketing how much protein the US group's yogurt contains.
Just Food has approached Danone and Chobani for comment.
The lawsuit, filed in New York, claims Chobani has presented a serving size so it shows the product has a comparable amount of protein to Danone's Oikos Pro.
"This conduct is particularly insidious when Chobani knows that healthcare providers and the federal government are directing the public to choose foods that offer higher concentrations of protein to maintain their health," Danone was quoted as saying by Reuters.
According to multiple media reports, Danone alleges Chobani is incorrectly marketing how much protein the US group's yogurt contains.
Just Food has approached Danone and Chobani for comment.
The lawsuit, filed in New York, claims Chobani has presented a serving size so it shows the product has a comparable amount of protein to Danone's Oikos Pro.
"This conduct is particularly insidious when Chobani knows that healthcare providers and the federal government are directing the public to choose foods that offer higher concentrations of protein to maintain their health," Danone was quoted as saying by Reuters.
2 months ago
Is CRVS a good stock to buy? We came across a bullish thesis on Corvus Pharmaceuticals, Inc. on Biotech Distilled's Substack. In this article, we will summarize the bulls' thesis on CRVS. Corvus Pharmaceuticals, Inc.'s share was trading at $11.15 as of June 8th.
Pressmaster/Shutterstock.com
Corvus Pharmaceuticals, Inc., a clinical stage biopharmaceutical company, engages in the development of product candidates that precisely target proteins that are critical to immune cell maturation and function in the United States. CRVS is positioned as a high-conviction immunology and oncology catalyst story built around soquelitinib, a first-in-class oral covalent ITK inhibitor designed to reprogram T-cell biology rather than broadly suppress immune function.
Read More: 15 AI Stocks That Are Quietly Making Investors Rich
Read More: Undervalued AI Stock Poised For Massive Gains: 10000% Upside Potential
Pressmaster/Shutterstock.com
Corvus Pharmaceuticals, Inc., a clinical stage biopharmaceutical company, engages in the development of product candidates that precisely target proteins that are critical to immune cell maturation and function in the United States. CRVS is positioned as a high-conviction immunology and oncology catalyst story built around soquelitinib, a first-in-class oral covalent ITK inhibitor designed to reprogram T-cell biology rather than broadly suppress immune function.
Read More: 15 AI Stocks That Are Quietly Making Investors Rich
Read More: Undervalued AI Stock Poised For Massive Gains: 10000% Upside Potential
2 months ago
This Week In ***** e podcast: Episode 211 — Oysters in ***** e
When you buy through links on our articles, Future and its syndication partners may earn a commission.
On Episode 211 of This Week In ***** e, Rod Pyle and Tariq Malik talk with Jacob Scoccimerra of Monolith ***** e.
When one ponders the diet of Mars-bound astonauts, oysters don't often come to mind... but they should. As it turns out, the plucky bivalves have much to offer ***** e voyagers, including water filtration and a ready source of protein.
Scoccimerra, formerly of Nanoracks, initiated a research project with students from the Harrisburg University of Science and Technology, to design, build, and operate a closed-circuit, automated support environment for oysters in a simulated ***** e ***** og. It's a fascinating discussion that may leave you hungry.
Download or subscribe to this show at: https://twit.tv/shows/this...
Get episodes ad-free with Club TWiT at https://twit.tv/clubtwit
https://www.yahoo.com/news...
When you buy through links on our articles, Future and its syndication partners may earn a commission.
On Episode 211 of This Week In ***** e, Rod Pyle and Tariq Malik talk with Jacob Scoccimerra of Monolith ***** e.
When one ponders the diet of Mars-bound astonauts, oysters don't often come to mind... but they should. As it turns out, the plucky bivalves have much to offer ***** e voyagers, including water filtration and a ready source of protein.
Scoccimerra, formerly of Nanoracks, initiated a research project with students from the Harrisburg University of Science and Technology, to design, build, and operate a closed-circuit, automated support environment for oysters in a simulated ***** e ***** og. It's a fascinating discussion that may leave you hungry.
Download or subscribe to this show at: https://twit.tv/shows/this...
Get episodes ad-free with Club TWiT at https://twit.tv/clubtwit
https://www.yahoo.com/news...
8 months ago
Boosting One Protein Reawakens Aging Brain Cells in Mice, Study Shows
A discovery by researchers from the Baylor College of Medicine in the US could lead to treatments that clear the troublesome aggregations of protein thought to play a key role in Alzheimer's disease.
Using mice bred to have a condition similar to the neurodegenerative disorder, the team found that elevated levels of a protein called Sox9 triggered specialized brain cells to go into clean-up overdrive, 'vacuuming' up plaques with increased efficiency.
In behavioral and memory tests, the treated mice also performed better
A discovery by researchers from the Baylor College of Medicine in the US could lead to treatments that clear the troublesome aggregations of protein thought to play a key role in Alzheimer's disease.
Using mice bred to have a condition similar to the neurodegenerative disorder, the team found that elevated levels of a protein called Sox9 triggered specialized brain cells to go into clean-up overdrive, 'vacuuming' up plaques with increased efficiency.
In behavioral and memory tests, the treated mice also performed better
8 months ago
Five years after its release, Google’s protein-mapping AlphaFold2 large-language model has “revolutionized science,” Nature reported, helping to boost key biological research from drug discovery to cancer ***** ysis.
Proteins are long molecules made of sequences of smaller ones. Their vital role in the body is dictated by their 3D shape, and for decades scientists have tried to predict how they “fold” from their 2D sequence. AlphaFold2 solved that problem in 2020, and scientists can now predict almost any protein’s shape with incredible precision.
More than 3 million people in 190 countries
Proteins are long molecules made of sequences of smaller ones. Their vital role in the body is dictated by their 3D shape, and for decades scientists have tried to predict how they “fold” from their 2D sequence. AlphaFold2 solved that problem in 2020, and scientists can now predict almost any protein’s shape with incredible precision.
More than 3 million people in 190 countries
8 months ago
Deep within your bone marrow, a specialized set of stem cells is busy pumping out new blood cells to sustain your body. As we age, these hematopoietic stem cells (or HSCs) become less productive, affecting our immune system and increasing our risk of conditions like anemia and cancer.
Now, scientists have found a way to rewind the clock in aging HSCs, which could potentially help to treat age-related blood and immune deficiencies.
Like most of our cells, HSCs contain tiny compartments known as lysosomes. These are the cells' recycling centers, where complex molecules like proteins and lipids
Now, scientists have found a way to rewind the clock in aging HSCs, which could potentially help to treat age-related blood and immune deficiencies.
Like most of our cells, HSCs contain tiny compartments known as lysosomes. These are the cells' recycling centers, where complex molecules like proteins and lipids
8 months ago
A build-up of sticky proteins in the brain is a key hallmark of Alzheimer's, thought to be closely linked to the disease's progression. Now scientists have found a new way to clear these harmful clumps in the brains of mice and the eyes of fruit flies.
This potentially promising Alzheimer's treatment involves an oral dose of arginine, an amino acid already used as a medication for conditions including chest pain and high blood pressure.
The discovery was made by a team from Kindai University and ******* an's National Institute of Neuroscience, who focused on the amyloid-beta plaques seen in
This potentially promising Alzheimer's treatment involves an oral dose of arginine, an amino acid already used as a medication for conditions including chest pain and high blood pressure.
The discovery was made by a team from Kindai University and ******* an's National Institute of Neuroscience, who focused on the amyloid-beta plaques seen in
